

# Quillivant XR - (5 mg/mL; Extended-release Oral Suspension)

| Generic Name          | Methylphenidate Hydrochloride   | Innovator            | Tris pharma         |
|-----------------------|---|----------------------|---------------------|
| Dosage                | 5 mg/mL; Extended-release Oral Suspension                               | Branded US Sales     | Less Than \$1000 mn |
| Probable FTF          | Less Than 5   | Known Para IV Filers | Less Than 5         |
| Other ANDA developers | More Than 5   | Tentative Approvals  | None                |
| Final Approvals       | None  | Generic Launches     | None                |
| Indication            | Indicated for the treatment of Attention Deficit Hyperactivity Disorder |                      |                     |
| Complexities          | Yes   |                      |                     |

## **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

### **Executive Summary**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

#### **Patent Status**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

### **Launch Timelines and Competition**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

# **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.